Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …

Nonalcoholic fatty liver disease (NAFLD) is common and partially heritable and has no
effective treatments. We carried out a genome-wide association study (GWAS) meta …

The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the
paucity of human-relevant models for target discovery and compound screening. Here we …

Few studies have explored the impact of rare variants (minor allele frequency< 1%) on
highly heritable plasma metabolites identified in metabolomic screens. The Finnish …

Metabolism-related fatty liver disease (MAFLD) is the most common form of chronic liver
disease in the world. Its pathogenesis is influenced by both environmental and genetic …

Background The association of a healthy lifestyle and the American Heart Association (AHA)
Life's Essential 8 (LE8) score with the risk of new-onset nonalcoholic fatty liver disease …

We report a multi-ancestry genome-wide association study on liver cirrhosis and its
associated endophenotypes, alanine aminotransferase (ALT) and γ-glutamyl transferase …

Background & Aims Non-alcoholic fatty liver disease (NAFLD) can progress to cirrhosis and
hepatic decompensation, but whether genetic variants influence the rate of progression to …

Background & Aims Non-alcoholic fatty liver disease (NAFLD) has a prevalence of∼ 25%
worldwide, with significant public health consequences yet few effective treatments. Human …

Background Nonalcoholic fatty liver disease (NAFLD) is prevalent worldwide and is
associated with the risk of many extrahepatic diseases. However, whether NAFLD is a risk …